BioRestorative Therapies (NASDAQ:BRTX – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.22, Zacks reports. The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.30 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%.
BioRestorative Therapies Stock Down 1.9 %
NASDAQ BRTX opened at $1.51 on Friday. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $3.67. The firm has a 50 day moving average of $1.63 and a two-hundred day moving average of $1.60. The stock has a market capitalization of $10.45 million, a PE ratio of -0.99 and a beta of 63.40.
Analyst Upgrades and Downgrades
Separately, Roth Mkm upped their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th.
BioRestorative Therapies Company Profile
BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
See Also
- Five stocks we like better than BioRestorative Therapies
- What Are Dividends? Buy the Best Dividend Stocks
- Top-Performing Non-Leveraged ETFs This Year
- Where Do I Find 52-Week Highs and Lows?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
